BioVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 2, 2018, details a material definitive agreement entered into by BioVie Inc. on July 3, 2018. The filing covers a private placement of securities, significant executive leadership changes, and amendments to the Company's corporate governance documents.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company secured an aggregate consideration of $3.2 million through the sale of 2,133,332 shares of newly created Series A Convertible Preferred Stock at $1.50 per share.
- Warrant Issuance: The Company issued warrants to purchase 213,333,200 shares of Class A Common Stock at an exercise price of $0.018 per share. Acuitas Group Holdings, LLC received an additional 833,333 warrants as a payoff for a prior note.
- Future Funding Option: Acuitas holds an option to purchase up to 200,000,000 additional shares of Common Stock at $0.015 per share within two weeks of the one-year anniversary, contingent on the Company failing to secure $3 million in non-dilutive grants by that date.
- Conversion Terms: Preferred Stock automatically converts into 100 shares of Common Stock upon the filing of a Certificate of Amendment increasing authorized shares to 800,000,000.
- Financial Statements: This filing does not provide revenue, profit, cash flow, or debt metrics. It focuses solely on the transaction terms.
Material Changes and Executive Leadership
- CEO Appointment: Terren Peizer, Chairman of Acuitas Group Holdings, LLC, was appointed Chief Executive Officer and a member of the Board of Directors, effective July 3, 2018.
- Executive Transition: Jonathan Adams, the prior CEO, resigned from that role but was appointed President and Chief Operating Officer. He remains on the Board.
- Employment Amendment: Mr. Adams' employment agreement was amended to extend the term through July 3, 2019, and includes a lump-sum payment provision equal to his remaining base salary in the event of death or termination without cause.
- Corporate Governance: The Company amended its Bylaws to separate the roles of President and CEO and filed a Certificate of Designation for the Series A Preferred Stock.
Risks, Contingencies, and Adjustments
- Price Adjustment Mechanisms: The purchase price and warrant exercise price are subject to retroactive adjustment if the volume-weighted average price of Common Stock falls below $0.015 in the five trading days following July 3, 2018.
- Intellectual Property Risk: If Mallinckrodt Pharmaceuticals Ireland Limited prevails in proceedings reducing the useful life of the Company's IP by more than 75%, the effective price per share will be adjusted to 50% of the then-effective price.
- Existing Obligations: The Company disclosed ongoing royalty obligations: 5% on net sales of BIV201 (allocated to LAT Pharma, PharmaIn, and The Barrett Edge) and up to $200,000 annually on terlipressin products to the University of Padova.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the use of proceeds and future funding, which are subject to uncertainties.
Investor Verification Checklist
- Verify the filing status of the Certificate of Amendment to increase authorized Common Stock to 800,000,000 shares.
- Monitor the volume-weighted average price of Common Stock over the five trading days following July 3, 2018, to determine if price adjustments are triggered.
- Review the status of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial and Appeal Board.
- Confirm the terms of the Subsequent Sale option held by Acuitas regarding the $3 million non-dilutive funding threshold.
- Examine the full text of the Securities Purchase Agreement and Warrant forms filed as Exhibits 10.1 and 4.1 for detailed covenants.